| Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434] | Draft guidance | Technology appraisal guidance | |
| Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332] | Draft guidance | Technology appraisal guidance | |
| Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071] | Draft guidance | Technology appraisal guidance | |
| Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110] | Draft guidance | Technology appraisal guidance | |
| Nemolizumab for treating prurigo nodularis [ID6451] | Draft guidance | Technology appraisal guidance | |
| Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221 | Draft guidance | Technology appraisal guidance | |
| Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317 | Draft guidance | Technology appraisal guidance | |
| Pembrolizumab with carboplatin and paclitaxel for untreated advanced or recurrent endometrial cancer [ID6381] | Draft guidance | Technology appraisal guidance | |
| Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369] | Draft guidance | Technology appraisal guidance | |
| Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043] | Draft guidance | Technology appraisal guidance | |